Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesProstate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit
European Journal of Cancer, 10/07/09
van Leeuwen PJ et al. – A relative reduction in Pca metastasis of 53% and Pca mortality of 37% was observed in the intervention population after 8.5years of observation. The impact of overdiagnosis, quality of life benefits and cost-effectiveness need to be assessed before population-based PSA screening can be recommended
Methods- Total of 11,970 men, aged 55–74years, included in intervention arm of the European Randomised Study of Screening for Prostate Cancer (ERSPC) section Rotterdam
- Control population 133,287 men, aged 55–74years, between 1998 and 1999 in Northern Ireland (NI)
- Men followed for Pca incidence, metastasis and cause of death until 31st December 2006
- Median age 63years at study entry
- In Rotterdam 94.2% of men and in NI 6% of men underwent PSA testing
- In Rotterdam 1153 men (9.6%) diagnosed with Pca with median baseline PSA of 5.1ng/ml
- In NI, 3962 men (3.0%, p<0.001) were diagnosed with Pca with median baseline PSA of 18.0ng/ml
- Relative risk of Pca metastasis during observation in the intervention population compared to control population 0.47 (95% confidence interval (CI), 0.35–0.63
- Relative risk of Pca-specific mortality also lower in intervention population compared to control population after median follow-up of 8.5years: 0.63 ; absolute mortality reduction was 1.8 deaths per 1000 men
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR
Medical Oncology, 12/08/09
Frequency of CYP1B1 homozygous genotype 355T/T in prostate cancer families from Poland
European Journal of Cancer Prevention, 12/08/09
Calcineurin Inhibitors Activate the Proto-Oncogene Ras and Promote Protumorigenic Signals in Renal Cancer Cells
Cancer Research, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor